Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study.

Blood
S J ProctorJohn R Goodlad

Abstract

The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n = 175). The central element was a phase 2 study of VEPEMB chemotherapy (n = 103, median age 73 years) incorporating comorbidity assessment. A total of 72 other patients were treated off-study but registered prospectively and treated concurrently with: ABVD (n = 35); CLVPP (n = 19), or other (n = 18). Of VEPEMB patients, 31 had early-stage disease (stage 1A/2A) and received VEPEMB 3 times plus radiotherapy. Median follow-up was 36 months. Complete remission (CR) rate (intention-to-treat) was 74% and 3-year overall survival (OS) and progression-free survival (PFS) were 81% and 74%, respectively. A total of 72 patients had advanced-stage disease (stage 1B/2B/3 or 4) and received VEPEMB 6 times. CR rate was 61% with 3-year OS and PFS of 66% and 58%, respectively. Of patients achieving CR, 13% with early-stage and 5% with advanced-stage disease progressed. Overall treatment-related mortality was 7%. In patients treated with curative intent with VEPEMB, ABVD, and CLVPP (n = 157), CR linked to several factors in univariate analysis. In a Cox regression model only, obtaining CR...Continue Reading

References

Nov 19, 1992·The New England Journal of Medicine·G P CanellosB A Peterson
Feb 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Colin D WeekesUNKNOWN Nebraska Lymphoma Study Group
Jun 25, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J ProctorU Tirelli
Oct 31, 2002·British Journal of Haematology·Gail L StarkUNKNOWN Northern Region Lymphoma Group
Sep 21, 1963·JAMA : the Journal of the American Medical Association·S KATZM W JAFFE
Dec 4, 2003·Acta Oncologica·Gunilla EnbladUNKNOWN Swedish Lymphoma Study Group
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A LevisUNKNOWN Intergruppo Italiano Linfomi (IIL)
May 27, 2004·JAMA : the Journal of the American Medical Association·Jay F PiccirilloEdward L Spitznagel
Aug 9, 2005·Critical Reviews in Oncology/hematology·Martine ExtermannUNKNOWN Task Force on CGA of the International Society of Geriatric Oncology
Jan 31, 2009·Critical Reviews in Oncology/hematology·S J ProctorM Sieniawski
Jan 1, 2002·Acta Oncologica·Gunilla EnbladBengt Glimelius

❮ Previous
Next ❯

Citations

Oct 12, 2012·International Journal of Hematology·Dennis A Eichenauer, Andreas Engert
Jun 20, 2014·Current Hematologic Malignancy Reports·Francesca Montanari, Catherine Diefenbach
Nov 30, 2013·Hematology/oncology Clinics of North America·Peter Borchmann
Sep 17, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J BishtonC P Fox
Jun 21, 2013·Hematological Oncology·Deepa JagadeeshAndrew M Evens
Apr 10, 2014·British Journal of Haematology·George A FollowsUNKNOWN British Committee for Standards in Haematology
Apr 23, 2014·Expert Opinion on Pharmacotherapy·Dennis A EichenauerVolker Diehl
Jan 8, 2015·Blood·Peter Johnson, Hayley McKenzie
Jul 28, 2012·Lancet·William Townsend, David Linch
Oct 19, 2016·Annals of Hematology·C MartínezUNKNOWN Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
Dec 9, 2016·Expert Review of Hematology·John Matthew R Pierce, Amitkumar Mehta
Nov 6, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boris BöllPeter Borchmann
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boris BöllPeter Borchmann
Mar 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew M Evens, Fangxin Hong
Nov 14, 2013·British Journal of Hospital Medicine·Toby A EyreGraham P Collins
Dec 30, 2017·Blood·David J Straus
Sep 5, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew M EvensPaul A Hamlin
Nov 9, 2018·British Journal of Haematology·Jemma Longley, Peter W M Johnson
Nov 9, 2018·British Journal of Haematology·Boris Böll, Helen Görgen
Sep 3, 2019·Hematological Oncology·Emanuele CenciniMonica Bocchia
Jun 6, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Richard T HoppeNdiya Ogba
Jul 28, 2020·Leukemia & Lymphoma·Lucie MeynardSophie Dimicoli
Dec 7, 2019·Hematology·Andrew M EvensKevin A David
Sep 19, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Graça M DoresLindsay M Morton
Apr 25, 2020·Current Treatment Options in Oncology·Jordan CarterAndrew M Evens
Mar 24, 2021·Current Treatment Options in Oncology·Xavier Andrade-Gonzalez, Stephen M Ansell

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved